论文部分内容阅读
目的:探讨心脏舒张功能障碍的逆转。方法:入选我院舒张功能障碍的病人223例,随机分为常规治疗组,给予丹参滴注液16g,1次/d;磷酸肌酸钠组:在常规治疗组基础上给予磷酸肌酸钠静脉滴注(轻度舒张功能障碍每日给药2.0g,中重度舒张功能障碍给药2.0g,2次/d),并采用彩色多普勒超声心动图观察二尖瓣口舒张早期峰值流速(E)、二尖瓣口舒张晚期峰值流速(A)、二尖瓣环舒张早期速度峰值(Ea)、二尖瓣环舒张晚期速度峰值(Aa),计算E/A值,Ea/Aa值,E/Ea值。连续治疗14d,并根据治疗前后临床症状、体征及彩色多普勒超声心动图各指标改善情况评价疗效。结果:治疗后,与常规治疗组比较,磷酸肌酸钠组患者的症状、体征显效率(53.8%比98.2%,62.5%比92.0%),综合疗效的显效率(11.43%比82.97%),E/A值[(0.82±0.15)比(1.20±0.24)]、Ea/Aa值[(0.88±0.23)比(1.56±0.31)]显著提高,E/Ea值[(9.89±3.15)比(5.84±2.12)]显著降低,P均<0.01。结论:舒张功能障碍早期发现和干预是可以逆转的,磷酸肌酸钠有显著的治疗作用,是逆转舒张功能障碍的首选药物。
Objective: To investigate the reversal of diastolic dysfunction. Methods: Totally 223 patients with diastolic dysfunction in our hospital were randomly divided into routine treatment group, given Danshen infusion solution 16g, 1 time / d; sodium creatine phosphate group: on the basis of routine treatment group given sodium phosphate phoshate (2.0g for mild diastolic dysfunction, 2.0g for moderate-severe diastolic dysfunction, and 2 times for d), and the peak early diastolic velocity of mitral valve was measured by color Doppler echocardiography (A), mitral annular early peak diastolic velocity (Ea), mitral annular early diastolic velocity peak (Aa), calculated E / A value, Ea / Aa value, E / Ea value. Continuous treatment of 14d, and according to the clinical symptoms and signs before and after treatment and color Doppler echocardiography each index to improve the situation to evaluate the curative effect. Results: Compared with the conventional treatment group, the symptoms and signs of the patients in the sodium creatinine group were significantly improved (53.8% vs 98.2%, 62.5% vs 92.0%), and the effective rates (11.43% vs 82.97% Ea value [(0.82 ± 0.15) vs (1.20 ± 0.24)] and Ea / Aa value [(0.88 ± 0.23) vs (1.56 ± 0.31) 5.84 ± 2.12)] significantly reduced, P <0.01. Conclusion: Early detection and intervention of diastolic dysfunction can be reversed. Sodium creatine phosphate has a significant therapeutic effect and is the drug of choice for reversing diastolic dysfunction.